ANALYSIS OF COST-OF-ILLNESS DUE TO TYPHOID FEVER IN TERTIARY HEALTH CARE HOSPITALS AND PHARMACEUTICAL EVALUATION OF DIFFERENT BRANDS USED IN THE TREATMENT

Muhammad Azeem¹², Humaira Naureen², Muhammad Iqbal Nasiri¹∗ and Muhammad Umair Saleem¹

¹Department of Pharmaceutics, Hamdard Institute of Pharmaceutical Sciences, Hamdard University Islamabad Campus, Pakistan
²Department of Pharmaceutics, Riphah Institute of Pharmaceutical Sciences, Islamabad, Pakistan

The objectives of the current study were to estimate the out-of-pocket costs of illness of blood culture-confirmed typhoid fever, as well as to evaluate the different brands of ciprofloxacin HCl used in the treatment of typhoid fever. Therefore, a comparative study was designed for the assessment of costs of treatment at sixteen public (Government sector) and private tertiary health care hospitals located in Rawalpindi and Islamabad, Pakistan. On the basis of prescriptions collected from the hospitals, seven different brands of ciprofloxacin HCl prescribed in the treatment of typhoid fever were purchased from retail pharmacies for quality assessment. The mean costs for fourteen days and seven days treatment were analyzed and the overall costs of treatment were high at private health care sectors than public sectors. Model independent approach like similarity factor (f²) was also applied to assess the similarity between the dissolution profiles of different brands, and result indicated that three brands were found to be similar with reference product, while, three were dissimilar. It can be concluded that this cost-effective analysis of antibiotics used in the typhoid fever, will help to the local regulatory body as well as WHO to update typhoid fever immunization recommendations. Ciprofloxacin was found an effective antibacterial agent in the treatment of typhoid fever and all brands met the pharmaceutical quality parameters. Thus, physicians, pharmacists and patients can select most appropriate quality brand for the therapy of typhoid fever.

INTRODUCTION

Typhoid fever, one of the important public health problems in developing countries, caused by Salmonella enterica serotype typhi (S. typhi)¹. Crump et al., estimated that there were approximately 21 million typhoid fever cases and 216000 deaths worldwide². In Asia and South Asia, highest incidence rate of typhoid fever was found i.e. more than 100 cases per 100,000 populations occurred each year. Another multicentric study of Asian countries, including China, India, Indonesia, Pakistan and Vietnam, estimated the incidence of typhoid fever ranged from 15.3 per 100,000 persons/year in China to 451.7 per 100,000/year in Pakistan. The rates were significantly higher in Pakistan and India as compare to Vietnam, Indonesia and China³. These high rates of incidence can be reduced by improving sanitary and health care conditions⁴. The treatment of typhoid fever was introduced in 1948 with chloramphenicol⁵. Since, it has been greatly concerned that multidrug resistant (MDR) strains of S. typhi showed resistance to the classical first-line anti-typhoid agents (Ampicillin, Chloramphenicol, Co-trimoxazole), which were used in 1980’s⁶&⁷. For empirical therapy of suspected typhoid fever, fluoroquinolones and third generation cephalosporin have become drugs of choice. Nevertheless, recent reports of reduced
susceptibility to these agents potentially increased the chance of re-emergence of untreatable typhoid fever and an increasing global burden. The definitive diagnosis of typhoid fever depends on the isolation of S. typhi organisms from the blood or bone marrow or stool. In developing countries like Pakistan, the main problem is the irrational prescribing of antibiotics by physicians. Pharmaceutical industries provide incentives to the physicians, which leads to irrational prescribing and ultimately increases the cost of illness. The trend of prescribing multinational company’s medicines is another important factor of increasing cost of treatment. Typhoid fever is the most common febrile illnesses encountered by practitioners in developing countries. Ciprofloxacin HCl is an antibiotic belong to the class, fluoroquinolones. It was first sold by Bayer Pharmaceuticals. Ciprofloxacin HCl has been prescribed by different practitioners in the therapy of suspected typhoid fever caused by Salmonella typhi. Selection of a safe, effective and economic brand of the same generic is one the key indicator for effective treatment of diseases. Costs of illness can be estimated from private and public points of view. Private cost of illness means the treatment cost tolerated by the patients themselves whereas, public cost of illness means total cost acquired by a healthcare provider, i.e. government. Therefore, in the current study, the costs of illness of typhoid fever at tertiary health care hospitals located at Rawalpindi and Islamabad, Pakistan and different brands of ciprofloxacin HCl used in the treatment of typhoid fever were estimated.

MATERIAL AND METHODS

Materials

Ciprofloxacin reference sample was kindly gifted by Pearl Pharmaceuticals, Islamabad. Acetonitrile (HPLC Grade), triethylamine, phosphoric acid and all other chemicals were procured from Merck (Darmstadt, Germany). Apparatus utilized for brands analysis were analytical balance (Sartorius, Germany), Tablet hardness tester (Erweka, Germany), Disintegration test apparatus (ED2-SAPO, Electrolab, India), Dissolution test apparatus (USP apparatus II, Electro Lab TDT 08L), Friabilator (Erweka, Germany), Sonicator (Isolab, Germany) and Magnetic stirrer (Isolab, Germany). Spectrophotometer (Shimadzu UV-1800) and HPLC (Shimadzu, Tokyo, Japan) with a UV detector (SPD-20A; Tokyo, Japan).

Methods

Study design

A comparative retrospective study was designed with the aimed, to assess the cost of illness, as well as to evaluate, which sectors (public or private) of health care of Pakistan is providing cost effective treatment for typhoid fever. Quantitative method was used for the purpose of data collection so that a cost effective and cost expensive treatment can be estimated.

Study settings, respondents and data sampling

A retrospective surveys were conducted on tertiary hospitals data located at Islamabad Capital and Rawalpindi, Pakistan. Both the cities feature a humid subtropical climate with long and very hot summers, a monsoon and short mild wet winters. In summer the maximum temperature can sometimes soar up to 46°C, while, it may drop to minimum of 4°C in winter. All the hospitals provides both inpatient and outpatient care. Collected data showed that most patients were treated as outpatients at these hospitals. The sampling unit was the hospital facility and sampling element was prescription. The prescriptions were analyzed and cost of treatment was calculated by determining the cost of antibiotics and antipyretics prescribed. Effect of brand prescribing on the cost of therapy was also assessed. Hospitals were randomly selected on the basis of accessibility to the data and cooperation. Total of sixteen well known hospitals were targeted, eight were public/government and eight were private hospitals. As per WHO standard, sample size of 30 prescriptions from each public and private tertiary health care hospitals were collected (see, Table 2).

Data collection procedure of prescriptions

The respondents were informed about the study designed. From each public and private sector hospitals, 30 prescriptions were taken,
thus, a total of 480 prescriptions were collected from 16 hospitals of Rawalpindi and Islamabad (8 public and 8 private) as given in Table 2. Moreover, the combinations of therapy for typhoid were separated and cost of prescription for seven and fourteen days were calculated for each combination. Treatment cost was calculated by calculating individual cost per therapy of antibiotics. Cost of therapy was calculated with the help of PharmaGuide Book\textsuperscript{13}.

**Data analysis of prescriptions**

After data collection, data was coded and analyzed by using SPSS version 16.0 (Statistical Package for the Social Sciences, used for complex statistical data analysis). Statistical analysis was done via Chi-Square test to find out the differences and association among variables.

**Collection and assessments of brands of ciprofloxacin 500 mg tablets**

Seven brands (four local and three multinational) of ciprofloxacin HCl 500 mg tablets were collected from retail pharmacies located at Islamabad, Pakistan and they were coded as Cipro-1, Cipro-2, Cipro-3, Cipro-4, Cipro-5, Cipro-6 and Cipro-7. Ciprofloxacin HCl 500 mg) tablets brands were characterized using\textsuperscript{14} and un-official methods for different pharmaceutical quality parameters such as, weight variation, hardness, friability, disintegration time and assay.

**Weight variation test**

Twenty tablets were selected randomly from each brand and individually weighed by using digital balance (Sartorius CP 224S, Germany). Average weight of tablet was calculated and percentage deviation was assessed for each brand. The limit for tablets weighing more than 500 mg was ±5%.

**Hardness test**

Sufficient strength are required to avoid breaking during handling, coating, filling and transportation. Limit for tablet hardness was set in between 5-10 kg/cm\textsuperscript{2} and tablets were checked through hardness tester (Erweka - TBH 125, Germany).

**Friability test**

The friability test of each brand was performed using friabilator (Erweka, Germany), operated for 4 min at a speed of 25 rotation/min. Friability test was performed by taking initial and final weight of 10 tablets and calculated by using equation \textsuperscript{15} The specification given in the USP for friability test is not more than 1%.

\[
\text{Friability} \% = \frac{\text{Initial Weight} - \text{Final Weight}}{\text{Initial Weight}} \times 100
\]

\[\text{…………………}(1)\]

**Disintegration test**

Disintegration test was performed by using USP disintegration apparatus (basket-rack assembly). Disintegration test was used to assess whether tablet disintegrates completely without any fragments remaining on the mesh of screen of the tubes under the prescribed experimental conditions. For this purpose, six tablets of each brand were placed in each six tubes. The assembly was operated in 0.1N HCl solution maintained at 37°C±2. The mean disintegration time of each tablets brand was determined. For film coated tablet disintegration time should not be more than 30 min\textsuperscript{16}.

**Drug content analysis**

Ten tablets of ciprofloxacin HCl were crushed into a uniform powder using mortar and pestle to evaluate for their drug content. It was performed by using HPLC method as stated in the official Pharmacopeia\textsuperscript{16}. The standard solution of ciprofloxacin was prepared by mixing 12.5 mg of ciprofloxacin reference standard in 50 mL volumetric flask containing mobile phase and then, 0.1 mL of 7% phosphoric acid was added, mixed and sonicated (Isolab, Germany) for 10 min. Then, 5 mL of this solution was transferred into another 25 mL flask to achieve an appropriate dilution of 50 µg/mL and volume was made up with same dilution. Similarly, an amount of 500 mg of the homogenized powder (equivalent to 1 tablet) was accurately weighed, transferred into a 100 mL volumetric flask and then added 0.2 mL of 7% phosphoric acid. Next, 70 mL of mobile phase was added to flask and sonicated for 15 min. The same diluent was used to make up the volume and then mixed for 30 min using magnetic stirrer.
(Isolab, Germany). Transferred 1 mL of the above solution into another 100 mL volumetric flask and made up volume with the same diluent, mixed and filtered through membrane filter having 0.45-micron pore size. After filtration, degassed and appropriate dilution to 50 µg/mL, the sample was injected into HPLC system (Shimadzu, Tokyo, Japan) consisted of UV detector set at 278 nm. The mobile phase used for analysis was composed of triethylamine and acetonitrile (87:13, v/v). An aliquot of 10 µL was injected into the HPLC system with auto-sampler (Shimadzu, Tokyo, Japan) and column temperature maintained at 30±1°C. The separation drug was performed with a flow rate of 1.5 mL/min and the retention time was observed 9.2 min. The chromatograms and area under curves were recorded and quantity of ciprofloxacin was calculated in mg for each sample.

Ciprofloxacin tablets should contain ciprofloxacin hydrochloride not less than 90% and not more than 110% of the labeled amount of ciprofloxacin[16].

**In-vitro drug release studies**

The multiple time dissolution test was performed on all the seven brands of ciprofloxacin tablet using USP dissolution type II (Paddle) apparatus. The paddle was rotated at 50 rpm for 30 min. Six tablets were individually placed in each dissolution vessel containing 900 mL of 0.1N HCl solution, maintained at 37±0.5°C. Aliquot of 5 mL was withdrawn at different time interval of 5, 10, 20 and 30 min and replaced with the same quantity of fresh medium. Then, 0.9 mL of sample was taken and diluted up to 50 mL with the dissolution medium to obtain a concentration of 10 µg/mL. The samples were filtered using filter paper of 0.45-micron pores size. The percentage released of ciprofloxacin was analyzed using UV spectrophotometer (Shimadzu UV-1800), by measuring the absorbance at 277 nm. USP specification claimed that not less than 80% of the labeled amount should release in 30 min[16].

**Release profile comparison**

The comparison was performed by using DD-solver software (An Add-In Program for Modeling and Comparison of Drug Dissolution Profiles)[17]. The similarity factor ($f_2$) provides simple interpretation of data to evaluate release profile of different brands as compare to reference (Cipro-1). If the values of $f_2$ are within range of 50 – 100%, it indicates similar profile and if $f_2$ values are less than 50%, it indicates that there is no similarity between two dissolution profiles, as explained by Zhang et al.[17] and Costa and Lobo[18].

**Statistical analysis**

All experiments were performed in triplicates and achieved data was analyzed using SPSS and all experimental data was reported as the means ± SD. Furthermore, Chi-Square test ($p \leq 0.05$) was applied to evaluate the variances among the cost of different brands of Ciprofloxacin HCl.

**RESULTS AND DISCUSSION**

There are two approaches of cost-of-illness studies i.e. prevalence based or incidence-based approach. The prevalence-based cost-of-illness studies measure the economic burden of a disease in a given period, whereas, the incidence-based approach measures the economic burden from the onset of disease until cure or death. The incidence-based approach was adopted in this study and was analyzed from the provider’s perspective[19]. Cost effective treatment regarding typhoid fever is not as much efficient in Pakistan as it should be. The average treatment duration for typhoid fever in case of I.V therapy is five to seven days and for oral treatment is almost two weeks[9]. The cost of therapy should be reasonable especially for lower class individuals so that they can bear it. According to WHO treatment guidelines for the management of typhoid fever (see, Table 1), the sensitive cases of typhoid should be treated with ciprofloxacin or ofloxacin and duration of therapy should be five to seven days. Cases with multidrug resistant species should be treated with cefixime, ceftriaxone and azithromycin for ten to fourteen days. While, severe illness and quinolone resistant typhoid cases, should be treated with cefotaxime, ceftriaxone and azithromycin for ten to fourteen days[9].
Table 1: WHO Guidelines (2011) of antimicrobial therapy for treatment of typhoid fever.

| Susceptibility         | Antibiotics                | Daily Dose (mg/kg) | Duration of therapy (Days) |
|------------------------|----------------------------|--------------------|---------------------------|
| Fully Sensitive        | Ciprofloxacin             | 15                 | 5 – 7 days                |
|                        | Ofloxacin                 | 15                 |                           |
| Multidrug Resistant    | As above Cefixime         | 15                 | 7 – 14                    |
|                        |                            | 15 – 20            |                           |
| Quinolone resistant    | Azithromycin              | 8 – 10             | 7                         |
|                        | Rocephin                  | 75                 | 10 – 14                   |
|                        |                            | 80                 |                           |
| Fully Sensitive        | Ciprofloxacin             | 15                 | 10 – 14                   |
|                        | Ofloxacin                 | 15                 |                           |
| Multidrug Resistant    | As above Cefixime         | 15                 | 10 – 14                   |
|                        |                            | 15 – 20            |                           |
| Quinolone resistant    | Azithromycin              | 8 – 10             | 10 – 14                   |
|                        | Rocephin                  | 75                 |                           |
|                        | Cefotaxime                | 80                 |                           |
| Alternative Effective  | Chloramphenicol           | 50 – 75            | 14 – 21                   |
| Antibiotics            | Amoxicillin               | 75 – 100           | 14                         |
|                        | Cotrimoxazole             | 8 – 40             | 14                         |

The study was conducted in Islamabad and Rawalpindi targeting both public and private tertiary health care hospitals. Total of 16 hospitals were visited, among them 8 were public and 8 were private hospitals. From each facility 30 prescriptions were collected and assessed for cost effectiveness. Thus, a total of 480 prescriptions were analyzed, i.e. 50% (240/480) from public sector and 50% (240/480) from private sector as mentioned in table 2.

Table 3 shows the frequency of antibiotics prescribed in term of percentage in different hospitals such as ciprofloxacin tablet 30.21% (145/480), Ceftriaxone injection 13.75% (66/480), Ciprofloxacin + Ceftriaxone 10.83% (52/480), Ciprofloxacin + Cefixime 9.79% (47/480) and Clarithromycin + Amoxicillin & Clavulanic acid 10% (48/480). However, the least prescribed antibiotics were Cefixime (1.25%) and Levofloxacin (1.25%), i.e. (6/480). Previously, different researchers estimated the costs of unspecified diarrheal disease and also estimated the aggregate costs of typhoid fever based on public health surveillance and hospital-based data.

Cost analysis of antibiotics prescribed in different public and private sector hospitals

Treatment cost for this study was achieved by multiplying the unit costs of all brands used. These costs were converted into US dollar ($) in 2014 rate (0.0098 USD = 1 PKR). The total costs ranges of different brands of antibiotics with generic names and their percentages are given in table 4. The results showed that the costs of 29.2% (140/480) of brands (Leflox, Novidat, Curitol, Tarivid, Ciprin, Cipval) prescribed by physicians for the treatment of typhoid fever were found in the range $0.98 – 9.80 (PKR 100 – 1000). The costs of 30% (144/480) brands (Cefspan, Cycin, Cefepime + Cefim, Tanzo + Ciproxcin, Tazocin + Novidat, Ciproxcin + Amoxicil, Ciproxcin + Oxidil + Cefim, Cefim + Novidat, Rocephin + Novidat, Axcin, Novidat, Ciproxcin + Cefim, Claritek) were ranged between $9.81 – 19.60 (PKR 1001 to 2000). Similarly, cost of illness of 8.3% (40/480) brands fell in between $19.61– $29.40 (PKR 2001 – 3000). While, 7.3% (35/480) brands (Cefspan + Klaricid, Cefim + Injection Novidat, Injection Oxidil + Cefim) found in the range of $29.41– 39.20 (PK R 3001 to 4000). The cost of 3.5% (17/480) antibiotics brands (Injection Cefepime + Cefim, Injection Salxone) were found in the range of $49.01 – 58.80 (PKR 5001 to 6000). The costs of 8.3% (40/480) brands (Inj. Rocephin + cefixime, Inj. Rocephin, Inj. Rocephin+ Novidat) fell between $58.81– 68.60 (PKR 6001 to 7000). The brands (Inj. Rocephin 2 g + Inj. Rocephin 1g, Inj. Rocephin 2 g, Inj. Rocephin 1 g + Inj.
Table 2: List of all public and private hospitals with number of prescriptions collected ($n=480$).

| S. No. | Name of hospitals | Public Sector (government) | Private Sector | No. of prescriptions | Percentage |
|--------|-------------------|-----------------------------|----------------|----------------------|------------|
| 1      | Military hospital Rawalpindi | Ahmad Medical Complex Rawalpindi | 30 + 30 | 6.25 + 6.25 |
| 2      | Railway hospital Rawalpindi | Safari hospital Rawalpindi | 30 + 30 | 6.25 + 6.25 |
| 3      | Pakistan Atomic Energy Commission General hospital Islamabad | Reliance hospital Islamabad | 30 + 30 | 6.25 + 6.25 |
| 4      | Pakistan Institute of Medical sciences Islamabad | Kulsum International hospital Islamabad | 30 + 30 | 6.25 + 6.25 |
| 5      | Nescom hospital Islamabad | Shifa International hospital Islamabad | 30 + 30 | 6.25 + 6.25 |
| 6      | CDA hospital Islamabad | Maryam hospital Rawalpindi | 30 + 30 | 6.25 + 6.25 |
| 7      | DHQ hospital Rawalpindi | Valley hospital Rawalpindi | 30 + 30 | 6.25 + 6.25 |
| 8      | Polyclinic hospital Islamabad | Maroof International hospital Islamabad | 30 + 30 | 6.25 + 6.25 |
| Total  |                  |                             | n=480 | 100% |

Table 3: Generic names of all antibiotics prescribed in all hospitals for the treatment of typhoid fever.

| S. No. | Generic name of antibiotics | No of prescriptions ($n=480$) | Percentages (%) |
|--------|-------------------------------|-----------------------------|-----------------|
| 1      | Ceftriaxone                   | 66                          | 13.75           |
| 2      | Cefixime                      | 6                           | 1.25            |
| 3      | Ciprofloxacin                 | 145                         | 30.21           |
| 4      | Levofloxacin                  | 6                           | 1.25            |
| 5      | Ofloxacin                     | 17                          | 3.54            |
| 6      | Vancomycin                    | 7                           | 1.46            |
| 7      | Clarithromycin                | 7                           | 1.46            |
| 8      | Ciprofloxacin + Ceftriaxone   | 52                          | 10.83           |
| 9      | Ciprofloxacin + Cefixime      | 47                          | 9.79            |
| 10     | Ciprofloxacin + Amoxicillin   | 8                           | 1.67            |
| 11     | Ciprofloxacin + Piperacillin  | 8                           | 1.67            |
| 12     | Ciprofloxacin + Piperacillin & Tazobactam | 8 | 1.67 |
| 13     | Ceftriaxone + Azithromycin    | 10                          | 2.08            |
| 14     | Ceftriaxone + Cefixime        | 24                          | 5.0             |
| 15     | Clarithromycin + Cefixime     | 11                          | 2.29            |
| 16     | Clarithromycin + Amoxicillin & Clavulanic acid | 48 | 10 |
| 17     | Cefepime + Cefixime           | 10                          | 2.08            |
| Total  |                               | 480                         | 100.0%          |
Table 4: Cost ranges of different brands of antibiotics with generic name prescribed in all hospitals.

| S. No. | Total cost of treatment ranges ($) | Brands name with generics                                                                 | No of prescriptions (n = 480) | Percentage (%) |
|--------|-----------------------------------|------------------------------------------------------------------------------------------|------------------------------|----------------|
| 1      | 0.98 – 9.80                       | • Leflox (Levofloxacin) • Novidat (Ciprofloxacin) • Curitol (Ofloxacin) • Tarivid (Ofloxacin) • Ciprin (Ciprofloxacin) • Cipval (Ciprofloxacin) | 140                          | 29.2           |
| 2      | 9.81 – 19.60                      | • Cefspan (Cefixime) • Cycin (Ciprofloxacin) • Inj. Cefpime + Cefim (Cefixime) • Inj. Tanzo (Piperacillin) + Ciproxcin (Ciprofloxacin) • Inj. Tazocin (Piperacillin & Tazobactam) + Novidat (Ciprofloxacin) • Ciproxcin (Ciprofloxacin) + Amoxicil (Amoxicillin) • Ciproxcin (Ciprofloxacin) • Oxidil (Ceftriaxone) + Cefim (Cefixime) • Cefim (Cefixime) + Novidat (Ciprofloxacin) • Inj. Rocephin (Ceftriaxone) + Novidat (Ciprofloxacin) • Axcin (Ciprofloxacin) • Novidat (Ciprofloxacin) • Ciprofloxacin + Cefim (Cefixime) • Claritek (Clarithromycin) | 144                          | 30.0           |
| 3      | 19.61 – 29.40                     | • Inj. Rocephin (Ceftriaxone) + Novidat (Ciprofloxacin) • Augmentin (Amoxicillin & Clavulanic acid) + Klaricid (Clarithromycin) • Ciproxcin (Ciprofloxacin) + Cefim (Cefixime) • Novidat (Ciprofloxacin) + Cefspan (Cefixime) • Ciproxcin, Novidat + Cefspan (Cefixime) | 40                           | 8.3            |
| 4      | 29.41 – 39.20                     | • Cefspan (Cefixime) + Klaricid • Cefim (Cefixime) + Inj. Novidat (Ciprofloxacin) • Inj. Oxidil (Ceftriaxone) + Cefim (Cefixime) | 35                           | 7.3            |
| 5      | 49.01 – 58.80                     | • Inj. Cefpime + Cefim (Cefixime) • Inj. Salxone (Ceftriaxone) | 17                           | 3.5            |
| 6      | 58.81 – 68.60                     | • Inj. Rocephin (Ceftriaxone) + Cefixime • Inj. Rocephin (Ceftriaxone) • Inj. Rocephin (Ceftriaxone) + Novidat (Ciprofloxacin) | 40                           | 8.3            |
| 7      | 68.61 – 156.80                    | • Inj. Rocephin 2g (Ceftriaxone) + Inj. Rocephin 1g (Ceftriaxone) • Inj. Rocephin 2g (Ceftriaxone) • Inj. Rocephin1g (Ceftriaxone) + Inj. Novidat (Ciprofloxacin) | 57                           | 11.9           |
| 8      | 156.81 – 186.20                   | • Vancomycin | 7 | 1.5 |
|        | Total                             |                                           | 480                          | 100.0%         |

Costs converted into USD ($) in 2014 rate, i.e. (1 USD = 101.649 PKR or 0.0098 USD = 1 PKR).
Novidat) having price range in between $68.61–156.80 (PKR 7001 – 16000) was 11.9% (57/480). While, costs of 1.5% (7/480) brand was found in the range of $156.81–186.20 (PKR 16001 to 19000).

Comparison of mean public and private costs of treatment due to typhoid fever

Table 5 indicates the relationship between costs of illness of public and private sector hospitals. After coding the costs in term of US dollar and other variables in the SPSS software, minimum cost of treatment, maximum cost, mean cost and standard deviation (SD) for seven and fourteen days treatment in public and private health care hospitals were evaluated. The minimum seven days costs in public sector hospital was found to be $3.61 (PKR 368) and in private it was $2.28 (PKR 233). The maximum costs for seven days treatment in public hospital was noted as $91.67 (PKR 9354), while, in private hospitals it was $77.88 (PKR 7947). The mean cost for seven days treatment in public and private hospitals were observed to be $7.20 (PKR 1436) and $4.57 (PKR 2627), respectively. Similarly, the mean cost for fourteen days treatment in public and private hospitals were found to be $26.66 (PKR 2720) and $45.82 (PKR 4676), accordingly. The minimum and maximum costs of illness in public hospitals for fourteen days was noted in the range of $7.20 – 183.34 (PKR 735 – 18708). While, in private hospitals it was found to be $4.57 – 155.76 (PKR 466 – 15894). For analysis, Chi-square test ($p \leq 0.05$) was applied. If $p \leq 0.05$, then, statistically significant differences between the cost of private and public sector hospitals. In the current study, a significant difference ($p \leq 0.000$) was observed among the costs of brands prescribed in different health care sectors. The average cost of treatment was relatively low in public hospitals as they were prescribing lesser amount of antibiotics in injectable form. While, private hospitals were prescribing multinational brands in the form of intravenous antibiotics which ultimately resulted in increased cost of treatment of typhoid fever in private sectors. This increased in costs in private sector hospitals was due to lesser use of oral antibiotics.

Assessments of different brands of ciprofloxacin 500 mg tablets

The labeling information of all brands are shown in table 6. Four local and three multinational brands of ciprofloxacin HCl 500 mg tablets were selected and coded as Cipro-1, Cipro-2, Cipro-3, Cipro-4, Cipro-5, Cipro-6 and Cipro-7. Table 7 shows physicochemical evaluation of all brands of ciprofloxacin HCl 500 mg tablets. The tablets brands were characterized using official$^{22}$ and un-official methods for different pharmaceutical quality parameters such as, weight variation, hardness, friability, disintegration time, assay and dissolution. Hardness of all brands was found satisfactory and the values were felt in between 8.10 – 11.20 kg/cm$^2$ (Table 7). Results of weight variation test of all brands were also found within the USP specification of ±5%, as listed in table 7$^{22}$. The friability test results of all brands was also found within the limits of <1% as specified in pharmacopeia$^{22}$. Similar types of findings were also reported by Saleem et al.$^{23}$ and Shah et al.$^{24}$.

| Sectors | No of prescription ($n=480$) | 7 days treatment | 14 days treatment | P-value |
|---------|-----------------------------|------------------|-------------------|---------|
|         |                             | Min. cost        | Max. cost         | Mean Cost ($) | SD | Min. cost | Max. cost | Mean Cost ($) | SD |         |
| Public  | 240                         | 3.61             | 91.67             | 14.07        | 20.62 | 7.20      | 183.34    | 26.66        | 40.74 | 0.000   |
| Private | 240                         | 2.28             | 77.88             | 25.74        | 22.01 | 4.57      | 155.76    | 45.82        | 41.10 |         |

Chi-Square test ($p \leq 0.05$): SD = standard deviation; $=$ US dollar.
Table 6: Labelling information of all brands of ciprofloxacin (500 mg) tablets.

| Brand Code | Company     | Batch Number | Expiry Date | Retail price per 10 tablets ($) |
|------------|-------------|--------------|-------------|---------------------------------|
| Cipro-1    | Multinational | KHO 2282    | 12/2019     | $4.95                           |
| Cipro-2    | Local       | 004A         | 12/2019     | $2.76                           |
| Cipro-3    | Local       | 6720         | 03/2018     | $2.89                           |
| Cipro-4    | Local       | 239          | 01/2019     | $2.16                           |
| Cipro-5    | Multinational | BDCWAH     | 12/2018     | $2.11                           |
| Cipro-6    | Multinational | J0466       | 12/2019     | $2.45                           |
| Cipro-7    | Local       | 002          | 11/2019     | $3.78                           |

Table 7: Physicochemical evaluation of all brands of ciprofloxacin HCl 500 mg tablets.

| Brand code | Weight variation**  (mg) | Hardness** (kg/cm²) | Friability** (%) | Disintegration Time*** (min) | Assay* (%) |
|------------|--------------------------|---------------------|-----------------|-----------------------------|------------|
| Cipro-1    | 784.3 ± 7.82             | 11.20 ± 2.20        | 0.31 ± 0.09     | 1.8                         | 98.60 ± 0.75 |
| Cipro-2    | 733.7 ± 6.78             | 8.10 ± 2.55         | 0.11 ± 0.11     | 1.1                         | 96.8 ± 0.54  |
| Cipro-3    | 894.7 ± 7.87             | 8.70 ± 4.12         | 0.31 ± 0.21     | 7.5                         | 97.5 ± 1.06  |
| Cipro-4    | 818.5 ± 6.05             | 9.50 ± 1.56         | 0.18 ± 0.36     | 3.3                         | 94.8 ± 1.32  |
| Cipro-5    | 670.9 ± 5.11             | 10.6 ± 2.07         | 0.20 ± 1.21     | 5.7                         | 101.7 ± 0.99 |
| Cipro-6    | 773.5 ± 6.24             | 9.80 ± 1.17         | 0.28 ± 1.21     | 2.6                         | 101.5 ± 0.99 |
| Cipro-7    | 726.3 ± 7.33             | 10.25 ± 2.21        | 0.34 ± 1.21     | 3.8                         | 97.8 ± 0.99  |

All values are expressed as mean ± SD;*n = 10; ** n = 20; *** n = 6.

Disintegration test
Disintegration test directly correlates how much the tablet will take to disintegrate and to absorb inside the body. The disintegration time of all brands was found in the range of 1.1–7.5 min (Table 7), indicating that all brands complying the USP acceptance limits of not more than 30 min. Results showed that Cipro-3 took more time (7.5 min), while, Cipro-2 took least time (1.1 min) to disintegrate. This slight variation may be due to differences in their formulation composition.

Assay of Ciprofloxacin tablets
Assay of Ciprofloxacin 500 mg tablets was performed using HPLC method as stated in the official Pharmacopeia. The assay results of all brands were found in the range of 96.8±0.54 to 101.7±0.99%, as illustrated in Table 7. The results were observed within the pharmacopoeial limits of 90–110.

In-vitro drug release studies
Multiple point dissolution study was performed for comparison of all the seven brands by using the USP dissolution type II apparatus at 50 rpm. The samples were withdrawn at a time interval of 5, 10, 20 and 30 min. The dissolution studies showed satisfactory results of all brands and complied the USP specification of not less than 80% at 30 min. The results of all three brands were in the range of 88.30 to 97.50% as shown in Table 8. Previously, moxifloxacin 400 mg tablet brands were evaluated and reported drug release in the range of 93.11–96.25%.
Table 8: Dissolution profile of all brands of Ciprofloxacin 500 mg tablet and similarity factor (f²).

| Brand Code | Mean dissolution rate at different time interval (%) | USP Limit | Similarity factor (f²) values (%) |
|------------|-----------------------------------------------------|-----------|----------------------------------|
|            | At 5 min  | At 10 min | At 20 min | At 30 min |                 |                    |
| Cipro-1    | 75.66     | 85.82     | 94.76     | 94.7      | Reference       |
| Cipro-2    | 70.21     | 83.50     | 90.37     | 92.8      | Cipro-1 & Cipro-2= 62.56 |
| Cipro-3    | 67.41     | 74.04     | 83.55     | 88.6      | Cipro-1 & Cipro-3= 46.51 |
| Cipro-4    | 61.52     | 77.20     | 89.5      | 91.4      | Cipro-1 & Cipro-4= 48.57 |
| Cipro-5    | 75.66     | 88.82     | 92.76     | 97.5      | Cipro-1 & Cipro-5= 80.73 |
| Cipro-6    | 66.48     | 80.20     | 92.34     | 93.9      | Cipro-1 & Cipro-6= 56.06 |
| Cipro-7    | 69.56     | 73.11     | 82.43     | 88.3      | Cipro-1 & Cipro-7= 45.89 |

Drug release profile comparison (Similarity Factor f² Value)
The similarity between dissolution profiles of other six brands as compare to reference product (Cipro-1) was assessed by applying similarity factor (f²) using DD Solver (an Excel add-in software)\(^1\). The observed f² values of brand Cipro-2, Cipro-5 and Cipro-6 were found within the range of 56.06–80.73%, which indicated that there were similarity in the release profile of these three brands of Ciprofloxacin 500 mg tablets when compared with reference brand. Similarly, the f² values of brand Cipro-3, Cipro-4 and Cipro-7 were found within the range of 45.89–48.57%, indicating dissimilarity between these brands as shown in table 8. According to the FDA guidelines, if the values of f² are within the range of 50 – 100%, it indicates equivalence and if the values are less than 50%, then, there is no similarity between two dissolution profiles\(^1\).

Conclusion
A retrospective study was designed to assess the cost of treatment and to evaluate which sectors (public or private) of health care of Pakistan is providing cost effective treatment for typhoid fever. Quantitative method was used for the purpose of data collection so that a cost effective and cost expensive treatment can be estimated. The quality parameters of seven Ciprofloxacin 500 brands were also evaluated such as weight variation, Hardness, friability, disintegration time, in-vitro dissolution and assay and results were found within the acceptance ranges of USP, with no significant difference in their results. Hence, the outcomes of the study revealed that all brands possess good pharmaceutical qualities. Therefore, findings of the current study revealed that prescribing practice in both public and private sector hospitals was in accordance with the standard guidelines treatment of WHO for typhoid fever. The average treatment cost for typhoid was greater in private tertiary health care sector as compared to public tertiary health care sector. It can also be concluded that low cost brand of Ciprofloxacin 500 brands can be prescribed and interchanged rather than costly brand.

Acknowledgements
Authors are thankful to the Department of Pharmaceutics, Riphah Institute of Pharmaceutical Sciences, Islamabad, Pakistan for providing data facilities.

Conflict of interest statement
Authors declared no conflict of interests.

Funding
For this projects no funding was available.

REFERENCES
1- M. Raffatellu, R. P. Wilson, S. E. Winter and A. J. Baumler, "Clinical pathogenesis of typhoid fever", The Journal of Infection in Developing Countries, 2, 260-266 (2008).
2- J. A. Crump, S. P. Luby and E. D. Mintz, "The global burden of typhoid fever", Bulletin of the World Health Organization, 82, 346 (2004).
3- R. L. Ochiai, C. J. Acosta, M. Danovaro-Holliday, D. Baiqing, S. K. Bhattacharya, M. D. Agtini, Z. A. Bhutta, D. G. Canh, M. Ali and S. Shin, "A study of typhoid
fever in five Asian countries: Disease burden and implications for controls", *ibid.*, 86, 260 (2008).

4- A. Owais, S. Sultana, U. Zaman, A. Rizvi and A. K. Zaidi, "Incidence of typhoid bacteremia in infants and young children in southern coastal Pakistan", *The Pediatric Infectious Disease Journal*, 29, 1035 (2010).

5- T. E. Woodward, J. E. Smadel, H. L. LEY, R. Green and D. Mankikar, "Preliminary report on the beneficial effect of chloromycetin in the treatment of typhoid fever", *Annals of Internal Medicine*, 29, 131 (1948).

6- S. Mirza, N. Beechmg and C. Hart, "Multi-drug resistant typhoid: A global problem", *Journal of Medical Microbiology*, 44, 317 (1996).

7- F. E. Abdullah, F. Haider, K. Fatima, S. Irfan and M. S. Iqbal, "Enteric fever in Karachi: Current antibiotic susceptibility of Salmonellae isolates", *Journal of the College of Physicians and Surgeons Pakistan*, 22, 147 (2012).

8- A. Kothari, A. Pruthi and T. D. Chugh, "The burden of enteric fever", *The Journal of Infection in Developing Countries*, 2, 253 (2008).

9- W. H. Organization, In: "Guidelines for the Management of Typhoid Fever" (2011).

10- N. Ngwuluka, K. Lawal, P. Olorunfemi and N. Ochekpe, "Post-market in-vitro bioequivalence study of six brands of ciprofloxacin tablets/caplets in Jos, Nigeria", *Scientific Research and Essays*, 4, 298 (2009).

11- D. Sur, S. Chatterjee, A. Riewpaiboon, B. Manna, S. Kanungo and S. K. Bhattacharya, "Treatment cost for typhoid fever at two hospitals in Kolkata, India", *Journal of Health, Population, and Nutrition*, 27, 725 (2009).

12- UN-Habitat, "Cities and Climate Change Initiative, A Bridged Report Islamabad-Pakistan, Climate Change Vulnerability Assessment", United Nations Human Settlements Programme (UN-Habitat) Islamabad (2014).

13- PharmaGuide, "Hand Book Published Annually Providing Essential Prescribing and Trade Information", 25th Edn. (2018).

14- USP35-NF30, "The United States Pharmacopeial Convention", USA (2013).

15- F. Qamar, S. Alam, S. Naveed and H. Ali, "Quality assessment and dissolution profile comparison studies on naproxen tablets available in Karachi", *RADS-J. Pharm. Pharm. Sci.*, 5, 32 (2017).

16- USP/NF, "The United States Pharmacopoeia 36/National Formulary", 31 (2013).

17- Y. Zhang, M. Huo, J. Zhou, A. Zou, W. Li, C. Yao and S. Xie, "DDSolver: An add-in program for modeling and comparison of drug dissolution profiles", *The AAPS Journal*, 12, 263 (2010).

18- P. Costa and J. M. S. Lobo, "Modeling and comparison of dissolution profiles", *European Journal of Pharmaceutical Sciences*, 13, 123 (2001).

19- E. Pagano, M. Brunetti, F. Tediosi and L. Garattini, "Costs of diabetes", *Pharmacoecnomics*, 15, 583 (1999).

20- S. Lerman, D. Shepard and R. Cash, "Treatment of diarrhoea in Indonesian children: What it costs and who pays for it", *The Lancet*, 326, 651 (1985).

21- N. H. Punjabi, "Cost evaluation of typhoid fever in Indonesia", *Medical Journal of Indonesia*, 7, 90-93 (1998).

22- UPS32/NF27, "The United States Pharmacopeial Convention", USA, 262 (2009).

23- A. Saleem, M. I. Nasiri, K. Zaheer, S. Anwer, T. Ali, H. Sarwar and S. S. Naqvi, "Comparative pharmaceutical equivalence studies of sofosbuvir 400 mg tablets available in Pakistani market", *Latin American Journal of Pharmacy*, 37, 2476 (2018).

24- M. R. Shah, M. I. Nasiri, S. Anwer, T. Ali, K. Zaheer, K. Ahmed and M. U. Saleem, "Pharmaceutical quality assessment of different brands of moxifloxacin 400 mg tablets available in Pakistan", *RADS Journal of Pharmacy and Pharmaceutical Sciences*, 7, 2 (2019).
تحليل تكلفة مرض حمى التيفوئيد في مستشفيات الرعاية المتخصصة والتقييم الصيدلاني للأدوية التجارية المختلفة المستخدمة في العلاج

محمد عظيم ٣٤ – حميرا نورين ٤ – محمد أقبال ناصر ٤ – محمد عمر سليم

قسم الصيدلانيات، معهد حمداز للعلوم الصيدلية، جامعة حمداز، إسلام أباد، باكستان
قسم الصيدلانيات، معهد ريفا للعلوم الصيدلية، جامعة ريفا الدولية، إسلام أباد، باكستان

كانت أهداف الدراسة الحالية هي تقدير تكلفة علاج حمى التيفوئيد، وكذلك تقييم العلامات التجارية المختلفة للسيبروفلوكساسين هيدروكلوريد المستخدم في العلاج. لذلك، تم تصميم دراسة مقارنة لتقييم تكلفة العلاج في ستة عشر مستشفى عام وخاص من مستشفيات الرعاية المتخصصة في روابند، وإسلام أباد، باكستان.

على أساس الوصفات الطبية التي تم جمعها من المستشفيات، تم شراء سبعة أنواع مختلفة من سيبروفلوكساسين هيدروكلوريد المرصوفة في علاج حمى التيفوئيد من صيدليات التجزئة لتقييم الجودة.

تم تحليل متوسط التكاليف لفترة علاج أربعة عشر يومًا ومتلك لفترة علاج سبعة أيام، وكانت التكاليف الإجمالية للعلاج مرتفعة في قطاعات الرعاية الصحية الخاصة مقارنة بالقطاعات العامة.

تم تطبيق النهج المستقل النموذجي مثل عامل التشابه (C) لتقييم التشابه بين أنماط الدواء لعلامات تجارية مختلفة، وأشارت النتيجة إلى أنه تم العثور على ثلاث علامات تجارية تتشابه مع المنتج المرجعي، بينما كانت ثلاث منها مختلفة.

يمكن استنتاج أن تحليل الفعالية من حيث التكلفة للمضادات الحيوية المستخدمة في حمى التيفوئيد، سيساعد الجهات المحلية وكذلك منظمة الصحة العالمية على تحديث توصيات التحصين ضد حمى التيفوئيد. وقد وجد أن سيبروفلوكساسين كان فعالًا كمضاد بكريري في علاج حمى التيفوئيد وجميع العلامات التجارية استوفت معايير الجودة الصيدلية. وعلى هذا يمكن للأطباء والصيدلاء والمرضى اختيار العلامة التجارية الأكثر ملاءمة لعلاج حمى التيفوئيد.